Status:
COMPLETED
Monitoring of the Mitochondrial Function of Circulating Myeloid Cells in Patients Hospitalized in the Intensive Care Unit of Dijon University Hospital
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Septicaemia
Eligibility:
All Genders
18-90 years
Brief Summary
Severe infections (sepsis) are a common cause of admission to the intensive care unit. They represent a significant health risk for patients in the short and medium term. They are particularly linked ...
Eligibility Criteria
Inclusion
- Adult person who has given written consent (or consent obtained from a heath care proxy) hospitalized in an ICU with or without sepsis (with or without infection)
Exclusion
- Person not affiliated or not benefiting from national health insurance
- Person under legal protection (curatorship, guardianship, safeguard of justice)
- Pregnant, parturient or breastfeeding woman
- Patient who was hospitalized within 3 months prior to inclusion for sepsis.
- Patients receiving known treatment for mitochondrial function modulation, mitochondrial biogenesis or mitophagy (chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil).
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2020
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04439617
Start Date
November 1 2019
End Date
March 30 2020
Last Update
July 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourgogne
Dijon, France, 21000